Kraj: Kanada
Język: angielski
Źródło: Health Canada
OXYBUTYNIN CHLORIDE
APOTEX INC
G04BD04
OXYBUTYNIN
5MG
TABLET
OXYBUTYNIN CHLORIDE 5MG
ORAL
100/500
Prescription
Antimuscarinics
Active ingredient group (AIG) number: 0114692001; AHFS:
APPROVED
2021-03-10
Page 1 of 23 PRODUCT MONOGRAPH PR OXYBUTYNIN Oxybutynin Chloride Tablets 5 mg, USP PR OXYBUTYNIN SYRUP Oxybutynin Chloride Syrup 1 mg / mL, USP ANTICHOLINERGIC / ANTISPASMODIC AGENT APOTEX INC. 150 Signet Drive Toronto, Ontario M9L 1T9 DATE OF PREPARATION: April 15,1997 DATE OF REVISION: March 8, 2021 Submission Control number #244366 Page 2 of 23 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .............................................................................. 3 SUMMARY PRODUCT INFORMATION ............................................................................................... 3 INDICATIONS AND CLINICAL USE ..................................................................................................... 3 CONTRAINDICATIONS ...................................................................................................................... 4 WARNINGS AND PRECAUTIONS ....................................................................................................... 4 ADVERSE REACTIONS ....................................................................................................................... 6 DRUG INTERACTIONS ...................................................................................................................... 9 DOSAGE AND ADMINISTRATION .................................................................................................... 9 OVERDOSAGE ................................................................................................................................. 10 ACTION AND CLINICAL PHARMACOLOGY .................................................................................. 11 STORAGE AND STABILITY ............................................................................................................... 12 DOSAGE FORMS, COMPOSITION AND PACKAGING ..................................................................... 12 PART II: SCIENTIFIC INFORMATION ............................................................................. Przeczytaj cały dokument